May 26, 2021 / 07:00PM GMT
Esther P. Rajavelu - UBS Investment Bank, Research Division - Analyst & Executive Director
And thank you for joining us at the UBS Virtual Healthcare Conference. We are lucky to have Chris Anzalone from Arrowhead Pharmaceuticals for this fireside chat. And without much ado, I'll go ahead and hand over to him to maybe set us up for this call, and then we'll jump into Q&A. (Operator Instructions)
So with that, Chris, why don't you just sort of walk us through what we should be expecting for the rest of the year and some of the key catalysts?
Christopher R. Anzalone - Arrowhead Pharmaceuticals, Inc. - CEO, President & Director
Sure. So thanks very much for having us, Esther. It's really a pleasure to be here. So the good news, bad news, with us is that we have a ton going on. We'll have -- we're going to have 10 clinical programs in no time. I think we'll double that to 20 in the next few years. And so we always have a lot to think about, a lot to talk about and a lot to look forward to. Over the next couple of months, we have a number of
Arrowhead Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference Transcript
May 27, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers